The Market Reports

Index

1 Opioid-Induced Constipation Market Overview
1.1 Product Overview and Scope of Opioid-Induced Constipation
1.2 Opioid-Induced Constipation Segment by Type
1.2.1 Global Opioid-Induced Constipation Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Methylnaltrexone Bromide
1.2.3 Lubiprostone
1.2.4 Naloxegol
1.2.5 Others
1.3 Opioid-Induced Constipation Segment by Application
1.3.1 Global Opioid-Induced Constipation Sales Comparison by Application: (2021-2027)
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Global Opioid-Induced Constipation Market Size Estimates and Forecasts
1.4.1 Global Opioid-Induced Constipation Revenue 2016-2027
1.4.2 Global Opioid-Induced Constipation Sales 2016-2027
1.4.3 Opioid-Induced Constipation Market Size by Region: 2016 Versus 2021 Versus 2027

2 Opioid-Induced Constipation Market Competition by Manufacturers
2.1 Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2016-2021)
2.2 Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Opioid-Induced Constipation Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Opioid-Induced Constipation Manufacturing Sites, Area Served, Product Type
2.5 Opioid-Induced Constipation Market Competitive Situation and Trends
2.5.1 Opioid-Induced Constipation Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Opioid-Induced Constipation Players Market Share by Revenue
2.5.3 Global Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Opioid-Induced Constipation Retrospective Market Scenario by Region
3.1 Global Opioid-Induced Constipation Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global Opioid-Induced Constipation Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America Opioid-Induced Constipation Market Facts & Figures by Country
3.3.1 North America Opioid-Induced Constipation Sales by Country
3.3.2 North America Opioid-Induced Constipation Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Opioid-Induced Constipation Market Facts & Figures by Country
3.4.1 Europe Opioid-Induced Constipation Sales by Country
3.4.2 Europe Opioid-Induced Constipation Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Opioid-Induced Constipation Market Facts & Figures by Region
3.5.1 Asia Pacific Opioid-Induced Constipation Sales by Region
3.5.2 Asia Pacific Opioid-Induced Constipation Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Opioid-Induced Constipation Market Facts & Figures by Country
3.6.1 Latin America Opioid-Induced Constipation Sales by Country
3.6.2 Latin America Opioid-Induced Constipation Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Opioid-Induced Constipation Market Facts & Figures by Country
3.7.1 Middle East and Africa Opioid-Induced Constipation Sales by Country
3.7.2 Middle East and Africa Opioid-Induced Constipation Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Opioid-Induced Constipation Historic Market Analysis by Type
4.1 Global Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
4.2 Global Opioid-Induced Constipation Revenue Market Share by Type (2016-2021)
4.3 Global Opioid-Induced Constipation Price by Type (2016-2021)

5 Global Opioid-Induced Constipation Historic Market Analysis by Application
5.1 Global Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
5.2 Global Opioid-Induced Constipation Revenue Market Share by Application (2016-2021)
5.3 Global Opioid-Induced Constipation Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Takeda Pharmaceuticals
6.1.1 Takeda Pharmaceuticals Corporation Information
6.1.2 Takeda Pharmaceuticals Description and Business Overview
6.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.1.5 Takeda Pharmaceuticals Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Bayer Opioid-Induced Constipation Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Mallinckrodt
6.4.1 Mallinckrodt Corporation Information
6.4.2 Mallinckrodt Description and Business Overview
6.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
6.4.5 Mallinckrodt Recent Developments/Updates
6.5 Salix (Bausch Health)
6.5.1 Salix (Bausch Health) Corporation Information
6.5.2 Salix (Bausch Health) Description and Business Overview
6.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
6.5.5 Salix (Bausch Health) Recent Developments/Updates
6.6 AstraZeneca
6.6.1 AstraZeneca Corporation Information
6.6.2 AstraZeneca Description and Business Overview
6.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
6.6.5 AstraZeneca Recent Developments/Updates
6.7 Progenics Pharmaceuticals
6.6.1 Progenics Pharmaceuticals Corporation Information
6.6.2 Progenics Pharmaceuticals Description and Business Overview
6.6.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
6.7.5 Progenics Pharmaceuticals Recent Developments/Updates
6.8 Purdue Pharm
6.8.1 Purdue Pharm Corporation Information
6.8.2 Purdue Pharm Description and Business Overview
6.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
6.8.5 Purdue Pharm Recent Developments/Updates
6.9 Nektar Therapeutics
6.9.1 Nektar Therapeutics Corporation Information
6.9.2 Nektar Therapeutics Description and Business Overview
6.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
6.9.5 Nektar Therapeutics Recent Developments/Updates
6.10 Daiichi Sankyo
6.10.1 Daiichi Sankyo Corporation Information
6.10.2 Daiichi Sankyo Description and Business Overview
6.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
6.10.5 Daiichi Sankyo Recent Developments/Updates
6.11 Prestige
6.11.1 Prestige Corporation Information
6.11.2 Prestige Opioid-Induced Constipation Description and Business Overview
6.11.3 Prestige Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Prestige Opioid-Induced Constipation Product Portfolio
6.11.5 Prestige Recent Developments/Updates
6.12 GSK
6.12.1 GSK Corporation Information
6.12.2 GSK Opioid-Induced Constipation Description and Business Overview
6.12.3 GSK Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.12.4 GSK Opioid-Induced Constipation Product Portfolio
6.12.5 GSK Recent Developments/Updates
6.13 Shionogi
6.13.1 Shionogi Corporation Information
6.13.2 Shionogi Opioid-Induced Constipation Description and Business Overview
6.13.3 Shionogi Opioid-Induced Constipation Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
6.13.5 Shionogi Recent Developments/Updates

7 Opioid-Induced Constipation Manufacturing Cost Analysis
7.1 Opioid-Induced Constipation Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Opioid-Induced Constipation
7.4 Opioid-Induced Constipation Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Opioid-Induced Constipation Distributors List
8.3 Opioid-Induced Constipation Customers

9 Opioid-Induced Constipation Market Dynamics
9.1 Opioid-Induced Constipation Industry Trends
9.2 Opioid-Induced Constipation Growth Drivers
9.3 Opioid-Induced Constipation Market Challenges
9.4 Opioid-Induced Constipation Market Restraints

10 Global Market Forecast
10.1 Opioid-Induced Constipation Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Opioid-Induced Constipation by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Opioid-Induced Constipation by Type (2022-2027)
10.2 Opioid-Induced Constipation Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Opioid-Induced Constipation by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Opioid-Induced Constipation by Application (2022-2027)
10.3 Opioid-Induced Constipation Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Opioid-Induced Constipation by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Opioid-Induced Constipation by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Opioid-Induced Constipation Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Opioid-Induced Constipation Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Opioid-Induced Constipation Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Opioid-Induced Constipation Covered in This Study
Table 5. Global Opioid-Induced Constipation Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Opioid-Induced Constipation Sales Market Share by Manufacturers (2016-2021)
Table 7. Global Opioid-Induced Constipation Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Opioid-Induced Constipation Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Opioid-Induced Constipation Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Opioid-Induced Constipation Manufacturing Sites and Area Served
Table 11. Manufacturers Opioid-Induced Constipation Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Opioid-Induced Constipation by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Opioid-Induced Constipation as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 16. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Table 17. Global Opioid-Induced Constipation Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 19. North America Opioid-Induced Constipation Sales Market Share by Country (2016-2021)
Table 20. North America Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)
Table 22. Europe Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 23. Europe Opioid-Induced Constipation Sales Market Share by Country (2016-2021)
Table 24. Europe Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Opioid-Induced Constipation Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Opioid-Induced Constipation Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)
Table 30. Latin America Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Opioid-Induced Constipation Sales Market Share by Country (2016-2021)
Table 32. Latin America Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Opioid-Induced Constipation Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Opioid-Induced Constipation Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Opioid-Induced Constipation Revenue Market Share by Country (2016-2021)
Table 38. Global Opioid-Induced Constipation Sales (K Units) by Type (2016-2021)
Table 39. Global Opioid-Induced Constipation Sales Market Share by Type (2016-2021)
Table 40. Global Opioid-Induced Constipation Revenue (Million US$) by Type (2016-2021)
Table 41. Global Opioid-Induced Constipation Revenue Share by Type (2016-2021)
Table 42. Global Opioid-Induced Constipation Price (USD/Unit) by Type (2016-2021)
Table 43. Global Opioid-Induced Constipation Sales (K Units) by Application (2016-2021)
Table 44. Global Opioid-Induced Constipation Sales Market Share by Application (2016-2021)
Table 45. Global Opioid-Induced Constipation Revenue (Million US$) by Application (2016-2021)
Table 46. Global Opioid-Induced Constipation Revenue Share by Application (2016-2021)
Table 47. Global Opioid-Induced Constipation Price (USD/Unit) by Application (2016-2021)
Table 48. Takeda Pharmaceuticals Corporation Information
Table 49. Takeda Pharmaceuticals Description and Business Overview
Table 50. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Takeda Pharmaceuticals Opioid-Induced Constipation Product
Table 52. Takeda Pharmaceuticals Recent Developments/Updates
Table 53. Bayer Corporation Information
Table 54. Bayer Description and Business Overview
Table 55. Bayer Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Bayer Opioid-Induced Constipation Product
Table 57. Bayer Recent Developments/Updates
Table 58. Sanofi Corporation Information
Table 59. Sanofi Description and Business Overview
Table 60. Sanofi Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. Sanofi Opioid-Induced Constipation Product
Table 62. Sanofi Recent Developments/Updates
Table 63. Mallinckrodt Corporation Information
Table 64. Mallinckrodt Description and Business Overview
Table 65. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Mallinckrodt Opioid-Induced Constipation Product
Table 67. Mallinckrodt Recent Developments/Updates
Table 68. Salix (Bausch Health) Corporation Information
Table 69. Salix (Bausch Health) Description and Business Overview
Table 70. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Salix (Bausch Health) Opioid-Induced Constipation Product
Table 72. Salix (Bausch Health) Recent Developments/Updates
Table 73. AstraZeneca Corporation Information
Table 74. AstraZeneca Description and Business Overview
Table 75. AstraZeneca Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. AstraZeneca Opioid-Induced Constipation Product
Table 77. AstraZeneca Recent Developments/Updates
Table 78. Progenics Pharmaceuticals Corporation Information
Table 79. Progenics Pharmaceuticals Description and Business Overview
Table 80. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Progenics Pharmaceuticals Opioid-Induced Constipation Product
Table 82. Progenics Pharmaceuticals Recent Developments/Updates
Table 83. Purdue Pharm Corporation Information
Table 84. Purdue Pharm Description and Business Overview
Table 85. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. Purdue Pharm Opioid-Induced Constipation Product
Table 87. Purdue Pharm Recent Developments/Updates
Table 88. Nektar Therapeutics Corporation Information
Table 89. Nektar Therapeutics Description and Business Overview
Table 90. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Nektar Therapeutics Opioid-Induced Constipation Product
Table 92. Nektar Therapeutics Recent Developments/Updates
Table 93. Daiichi Sankyo Corporation Information
Table 94. Daiichi Sankyo Description and Business Overview
Table 95. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Daiichi Sankyo Opioid-Induced Constipation Product
Table 97. Daiichi Sankyo Recent Developments/Updates
Table 98. Prestige Corporation Information
Table 99. Prestige Description and Business Overview
Table 100. Prestige Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. Prestige Opioid-Induced Constipation Product
Table 102. Prestige Recent Developments/Updates
Table 103. GSK Corporation Information
Table 104. GSK Description and Business Overview
Table 105. GSK Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. GSK Opioid-Induced Constipation Product
Table 107. GSK Recent Developments/Updates
Table 108. Shionogi Corporation Information
Table 109. Shionogi Description and Business Overview
Table 110. Shionogi Opioid-Induced Constipation Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 111. Shionogi Opioid-Induced Constipation Product
Table 112. Shionogi Recent Developments/Updates
Table 113. Production Base and Market Concentration Rate of Raw Material
Table 114. Key Suppliers of Raw Materials
Table 115. Opioid-Induced Constipation Distributors List
Table 116. Opioid-Induced Constipation Customers List
Table 117. Opioid-Induced Constipation Market Trends
Table 118. Opioid-Induced Constipation Growth Drivers
Table 119. Opioid-Induced Constipation Market Challenges
Table 120. Opioid-Induced Constipation Market Restraints
Table 121. Global Opioid-Induced Constipation Sales Forecast by Type (2022-2027) & (K Units)
Table 122. Global Opioid-Induced Constipation Sales Market Share Forecast by Type (2022-2027)
Table 123. Global Opioid-Induced Constipation Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 124. Global Opioid-Induced Constipation Revenue Market Share Forecast by Type (2022-2027)
Table 125. Global Opioid-Induced Constipation Sales Forecast by Application (2022-2027) & (K Units)
Table 126. Global Opioid-Induced Constipation Sales Market Share Forecast by Application (2022-2027)
Table 127. Global Opioid-Induced Constipation Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 128. Global Opioid-Induced Constipation Revenue Market Share Forecast by Application (2022-2027)
Table 129. Global Opioid-Induced Constipation Sales Forecast by Region (2022-2027) & (K Units)
Table 130. Global Opioid-Induced Constipation Sales Market Share Forecast by Region (2022-2027)
Table 131. Global Opioid-Induced Constipation Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 132. Global Opioid-Induced Constipation Revenue Market Share Forecast by Region (2022-2027)
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Opioid-Induced Constipation
Figure 2. Global Opioid-Induced Constipation Market Share by Type in 2020 & 2027
Figure 3. Methylnaltrexone Bromide Product Picture
Figure 4. Lubiprostone Product Picture
Figure 5. Naloxegol Product Picture
Figure 6. Others Product Picture
Figure 7. Global Opioid-Induced Constipation Market Share by Application in 2020 & 2027
Figure 8. Hospital
Figure 9. Pharmacy
Figure 10. Other
Figure 11. Global Opioid-Induced Constipation Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Opioid-Induced Constipation Market Size 2016-2027 (US$ Million)
Figure 13. Global Opioid-Induced Constipation Sales 2016-2027 (K Units)
Figure 14. Global Opioid-Induced Constipation Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 15. Opioid-Induced Constipation Sales Share by Manufacturers in 2020
Figure 16. Global Opioid-Induced Constipation Revenue Share by Manufacturers in 2020
Figure 17. The Global 5 and 10 Largest Opioid-Induced Constipation Players: Market Share by Revenue in 2020
Figure 18. Opioid-Induced Constipation Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 19. Global Opioid-Induced Constipation Sales Market Share by Region (2016-2021)
Figure 20. Global Opioid-Induced Constipation Sales Market Share by Region in 2020
Figure 21. Global Opioid-Induced Constipation Revenue Market Share by Region (2016-2021)
Figure 22. Global Opioid-Induced Constipation Revenue Market Share by Region in 2020
Figure 23. U.S. Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Canada Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Germany Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. France Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. U.K. Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Italy Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Russia Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. China Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. Japan Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. South Korea Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. India Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Australia Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Taiwan Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Indonesia Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Thailand Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Malaysia Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Philippines Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Vietnam Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Mexico Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Brazil Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Argentina Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Turkey Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Saudi Arabia Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. U.A.E Opioid-Induced Constipation Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. Sales Market Share of Opioid-Induced Constipation by Type (2016-2021)
Figure 48. Sales Market Share of Opioid-Induced Constipation by Application (2016-2021)
Figure 49. Sales Market Share of Opioid-Induced Constipation by Application in 2020
Figure 50. Revenue Share of Opioid-Induced Constipation by Application (2016-2021)
Figure 51. Revenue Share of Opioid-Induced Constipation by Application in 2020
Figure 52. Manufacturing Cost Structure of Opioid-Induced Constipation
Figure 53. Manufacturing Process Analysis of Opioid-Induced Constipation
Figure 54. Opioid-Induced Constipation Industrial Chain Analysis
Figure 55. Channels of Distribution
Figure 56. Distributors Profiles
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed